Abstract：
Pulmonary hypertension (PH) is a complex cardiovascular condition that is characterized by elevated pulmonary arterial pressure, which leads to significant morbidity and mortality. Among the various factors that influence the pathophysiology and progression of PH, iron deficiency has become a critical, yet often overlooked, element. In this review, the prevalence, implications, and therapeutic potential of addressing iron deficiency in patients with PH are elucidated.Iron deficiency, which is prevalent in a significant proportion of patients with PH, has been associated with worsened clinical outcomes, including diminished exercise capacity, impaired oxygen transport and utilization, and compromised right ventricular function. The pathophysiological linkages between iron deficiency and PH are multifaceted and involve alterations in oxygen sensing, endothelial function, and metabolic disturbances.In this review, the evidence from recent clinical trials and studies that assess the impact of iron supplementation, both oral and intravenous, on PH outcomes is critically analyzed. Although some studies suggest improvements in exercise capacity and hemodynamic parameters following iron repletion, the responses appear variable and are not universally beneficial. This review highlights the complexities of iron metabolism in PH and the challenges in effectively diagnosing and treating iron deficiency in this patient population.Furthermore, the potential mechanisms through which iron supplementation might influence pulmonary vascular and right ventricular function, emphasizing the need for personalized treatment approaches are discussed. In this review, the importance of recognizing iron deficiency in the management of patients with PH is highlighted, and further research is warranted to establish comprehensive, evidence-based guidelines for iron supplementation in this unique patient cohort. The ultimate goal of this review is to improve clinical outcomes and quality of life for patients suffering from this debilitating condition.
摘要：
肺动脉高压（PH）是一种复杂的心血管疾病，其特征是肺动脉压升高，导致显著的发病率和死亡率。在影响PH病理生理和进展的各种因素中，缺铁已经成为一个关键,但经常被忽视，元素。在这次审查中,患病率,含义，阐明了解决PH患者缺铁的治疗潜力。缺铁,这在很大一部分PH患者中很普遍，与恶化的临床结果有关，包括运动能力下降，氧气输送和利用受损，右心室功能受损.缺铁和PH之间的病理生理联系是多方面的，涉及氧传感的改变。内皮功能，和代谢紊乱。在这次审查中,来自最近的临床试验和评估铁补充剂影响的研究的证据，口服和静脉注射，对PH结果进行了严格分析。尽管一些研究表明铁补充后运动能力和血液动力学参数有所改善，反应似乎是可变的，并不是普遍有益的。这篇综述强调了PH中铁代谢的复杂性以及有效诊断和治疗该患者人群铁缺乏症的挑战。此外，铁补充可能影响肺血管和右心室功能的潜在机制，强调个性化治疗方法的必要性进行了讨论。在这次审查中,强调了认识缺铁在PH患者管理中的重要性，需要进一步的研究来建立全面的，在这个独特的患者队列中，基于证据的铁补充指南。这篇综述的最终目标是改善患有这种衰弱状况的患者的临床结果和生活质量。
